Clinical trials: Anti-NMDAR Encephalitis, open to volunteers
Anti-N-Methyl-D-Aspartate Receptor Encephalitis
Safety and Efficacy of Combined B Cell Depleting theRapy And Daratumumab In Autoimmune Encephalitis
Autoimmune encephalitis is an autoimmune disease of the central nervous system that targets neuronal autoantigens. Anti-neuronal autoantibodies are produced in patients, with anti-NMDAR antibody being the most common.Anti-NMDAR…
- Trial name
- RADIA (NCT06867991)
- Testing
- Ofatumumab combined with daratumumab, Ofatumumab, Repeated intravenous immunoglobulin/plasma exchange therapy
- Where
- 2 sites in China
- Volunteers
- 200 people
- Sponsor
- The First People's Hospital of Changzhou
Autoimmune Encephalitis, Anti-NMDAR Encephalitis
Clinical Evaluation of a Novel DAB Chromogenic Tissue-Based Assay for Detecting Anti-GABABR Antibodies
This multicenter, blinded, cross-sectional study aims to evaluate the clinical performance of a novel DAB chromogenic tissue-based assay (TBA) for detecting anti-GABAB receptor (anti-GABABR) antibodies.
- Conditions
- Autoimmune Encephalitis, Anti-NMDAR Encephalitis, Anti-GABABR Encephalitis
- Trial name
- GREAT (NCT07858175)
- Where
- 5 sites in China
- Volunteers
- 300 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Anti-N-Methyl-D-Aspartate Receptor Encephalitis
Efficacy and Safety of Taitacept in Treatment of Refractory or Recurrent Anti-NMDAR/anti-LGI1 Encephalitis
The main objective is to explore the efficacy and safety of Telitacicept in the treatment of refractory/recurrent anti-NMDAR and anti-LGI1 encephalitis.
- Trial name
- NCT06510283
- Testing
- Taitacept
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Beijing Tongren Hospital
Autoimmune Encephalitis, Encephalitis
The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis
Determine the difference in the modified Rankin score at 16 weeks in participants with anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis treated with "first-line" immunomodulatory therapies provided as standard-of-care, and…
- Trial name
- ExTINGUISH (NCT04372615)
- Testing
- Inebilizumab
- Where
- 39 sites in United States, Netherlands and 1 more
- Volunteers
- 116 people
- Sponsor
- University of Utah
Optic Neuritis, Transverse Myelitis
Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD)
The Swiss-Ped-IBrainD is a national patient registry that collects information on diagnosis, symptoms, treatment, and follow-up of pediatric patients with an inflammatory brain disease in Switzerland.
- Conditions
- Optic Neuritis, Transverse Myelitis, Acute Disseminated Encephalomyelitis, Multiple Sclerosis
- Trial name
- NCT05017142
- Where
- 13 sites in Switzerland
- Volunteers
- 500 people
- Sponsor
- University of Bern
Anti-N-methyl-D-aspartate Receptor (NMDAR) Encephalitis (ANRE), Anti-N-methyl-D-aspartate Receptor (NMDAR) Antibody-associated Psychiatric Disease
A Study in Participants With Anti-NMDAR Encephalitis and Anti-NMDAR Autoantibody-Associated Psychiatric Disease
This study will evaluate the safety, tolerability, preliminary efficacy and pharmacokinetics (PK) of ART5803 in adult participants with a confirmed diagnosis of anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis (ANRE) or…
- Conditions
- Anti-N-methyl-D-aspartate Receptor (NMDAR) Encephalitis (ANRE), Anti-N-methyl-D-aspartate Receptor (NMDAR) Antibody-associated Psychiatric Disease, Autoimmune Encephalitis
- Trial name
- NCT07093333
- Testing
- ART5803, ART5803-Cohort D
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Arialys Australia Pty Ltd
Encephalitis Autoimmune
Efgartigimod in Anti-NMDA Receptor Encephalitis.
This study is a multicenter, open-label, single-arm exploratory trial designed to enroll 20 eligible patients with anti-NMDAR encephalitis.
- Trial name
- ANSWER (NCT07822776)
- Testing
- Efgartigimod Alfa
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Beijing Tongren Hospital